@entity1860 ( @entity1860 ) is a @entity6961 characterized by the presence of an acquired mutation which affects the hematopoietic stem cell, leading to a striking overproduction of immature granulocytes. The first important clue to its pathogenesis the @entity8487 chromosome created by a reciprocal translocation between chromosomes 9 and 22 (t [9; 22] [q34; q11]). The development of the @entity1861 -targeted imatinib mesylate represents a paradigm shift in the treatment of @entity1860 . Imatinib displays inhibitory activity against other kinase(s) that play a role in monocyte/macrophage development. Accordingly many studies revealed the role of cytokines in pathophysiology of myeloid @entity5 including participation of @entity1356 in the pathogenesis of @entity1860 . This study designed to assess the behavior of @entity1356 through newly diagnosed @entity1 , different responders groups (optimal, suboptimal and failure cytogenetic response) and advanced stages (acceleration and crisis groups) of @entity1860 Iraqi @entity1 whom receiving Imatinib mesylate (tyrosine kinase inhibitor), trying to elucidate the role of immunity in pathophysiology of @entity1860 development and treatments. In this study 96 Iraqi @entity1860 @entity1 under imatinib mesylate treatment categorized by complete blood picture and fluorescent in situ hybridization analysis into different response groups and stages, then used an enzyme linked immunosorbent assay technique to assess serum level of @entity1356 in each response group and advance stage (acceleration and transformed) of @entity1860 @entity1 , in comparison to level in 32 healthy control subjects and 32 newly diagnosed @entity1860 . Out of 128 @entity1 the mean serum of @entity1356 level (pg/ml) for the newly diagnosed, optimal responded, suboptimal responded, failure cytogenetic and advance stage of @entity1860 were 6.53      3.81, 18.47      4.29, 18.69      3.03, 5.73      2.44, and 18.10      3.10, respectively. While healthy was 12.17      3.44. The measurement of @entity1356 before and during treatment of @entity1860 @entity1 may contribute to the early identification of responder and non responder @entity1 , and help in the earlier choice and/or design of alternative therapeutic strategies.

Assessment of XXXX serum level in different responder groups and stages of chronic myeloid leukemia @entity1 on imatinb mesylate therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1861 :: ('25', 'Gene') :: ['BCR-ABL'] @entity8487 :: ('MESH:D010677', 'Disease') :: ['Philadelphia'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b', 'interleukin 1b'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasia'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'Chronic myeloid leukemia', 'CML disease'] @entity6961 :: ('MESH:D009196', 'Disease') :: ['myeloproliferative disorder']
@entity1356 :: (3553,Gene) :: ['interleukin 1b']
